Pluristem’s Radiation Antidote Addresses $11 Billion Hematologic Indication in Human Trials
Proven efficacious as an antidote for Acute Radiation Syndrome (ARS) with data recently published from studies conducted by the U.S. National Institutes of Health (NIH), Pluristem Therapeutics™ (NASDAQ: PSTI) PLX-R18 cell therapy addresses an even […]